EN 中文
Home Strategic Partnerships News Contact us


Management Team

Dr. Li Xiaoyi
Chairman & CEO
Dr. Li Xiaoyi
Dr. Li Xiaoyi, aged 59, was appointed as the chairman of the Board, an executive Director and the CEO on January 20, 2017. He is mainly responsible for the formulation of the corporate development strategies and direction for our Group as well as overall day-to-day management of our business and operations. Dr. Li Xiaoyi also holds directorship at each subsidiary of our Group since its establishment. Dr. Li has over 25 years of experience in pharmaceutical R&D as well as management and strategic planning for pharmaceutical companies. Dr. Li founded Lee’s Pharm in 1994 and has been the chief technical officer since then. Dr. Li was appointed as an executive director and the chief executive officer of Lee’s Pharm in September 2003, where he is responsible for the overall operations and management and R&D of Lee’s Pharm and Dr. Li resigned as the chief executive officer and the chief technical officer and has been re-designed from an executive director to a non-executive director of Lee’s Pharm since April 29, 2021. In addition to his roles in Lee’s Pharm, Dr. Li also has multiple experience in the management and strategic planning for many other pharmaceutical institutions. Since 2014, he has been serving as the vice president of Hong Kong Biotechnology Organization, mainly responsible for developing the biotech industry in Hong Kong. Since March 2016, he has been serving as the president of Guangzhou Pharmaceutical Association* (广州医学会), an academic and non-profit social organization formed by pharmaceutical researchers in Guangzhou, where he is mainly responsible for providing industrial insights for developing the pharmaceutical industry in Guangzhou. Dr. Li is also a member of the review committee of Innovation and Technology Fund of Hong Kong Government, a fund supported by the government of Hong Kong to promote and facilitate technology companies. Dr. Li obtained his Ph.D. in pharmacology from the medicine college of the University of Illinois in the United States in May 1992. Dr. Li has earned multiple awards and esteemed recognitions. He has been an adjunct professor at the Hong Kong University of Science and Technology since November 2013 and an honorary fellow since June 2016. In August 2018, he was awarded the leading innovation talent* ( 广州创新领军人才 ) by the Guangzhou government. In January 2018, Dr. Li was appointed as a member of the People’s Political Consultative Conference of Anhui Province in the PRC, and was honored with the 16th World Outstanding Chinese Award (世界杰出华人奖) by the World Chinese Business Investment Foundation (世界华商投资基金会) in August 2018.
Dr. Lau Lit Fui
President & Chief Scientific Officer
Dr. Lau Lit Fui
Dr. Lau Lit Fui, aged 59, joined our Group in October 2012 and was appointed as president and chief operating officer of our Group on April 1, 2019 and reassigned as CSO on January 18, 2022. He is primarily responsible for overseeing the overall scientific functions of our Group, including basic and applied research projects, as well as the development of new processes, technologies or projects. He is also responsible for promoting the efficiency, profitability and competitive position of our Group.
Dr. Lau has 24 years of extensive experience in operation management and R&D of new drugs. From August 1998 to January 2008, he worked in the global R&D department of Pfizer Inc., a worldwide leading pharmaceutical company, where his last position was senior principal scientist heading a biology laboratory and supervising technicians in testing drug candidates. From January 2008 to August 2012, Dr. Lau worked as the associate director of the new product and alliance development department of GlaxoSmithKline (China) R&D Co., Ltd., a science-led global healthcare company, where he was responsible for department management and R&D of new drugs treating neurodegenerative diseases. Dr. Lau joined Lee’s Pharm in October 2012 and had been managing the operation and R&D of Lee’s Pharm until April 2016. Dr. Lau obtained both his bachelor’s degree in science and master degree of philosophy from The Chinese University of Hong Kong in December 1985 and December 1987, respectively, where he was awarded the Wong Siew Chan Scholarship. In December 1993, he obtained his Ph.D. in biochemical science from the University of Connecticut in the United States. He completed his research fellowship in neuroscience at the School of Medicine of John Hopkins University in the United States in August 1998. Dr. Lau’s outstanding performances have been recognized by several leading corporations. In February 1991, he was granted SmithKline Beecham Student Pharmacology Award by SmithKline Beecham Pharmaceuticals, a company focused on pharmaceuticals, biologics, vaccines, and consumer healthcare. During his employment with Pfizer, Inc., he was granted several awards by the global research & development department of the company, for his leadership, team work spirit and contribution in R&D. In 2014, he was awarded the Medicines for Life Award by UTASIA Inc., a subsidiary of United Therapeutics Corporation, a company mainly focusing on pharmaceutical preparations business. In 2018, Dr. Lau received an award from CVie Therapeutics Co. Ltd., a subsidiary of Lee’s Pharm, for his sustained contribution and commitment.
Ms. Lisa Feng
Chief Business Officer & Chief Financial Officer
Ms. Lisa Feng
Ms. Feng Xinyan, aged 44, was appointed as the CFO of our Group on December 7, 2020 and appointed for another dual role as the CBO on January 18, 2022. She is primarily responsible for financial planning and initiatives and investor relations management, and also oversees the overall operation of our Group.
From 2000 to 2002, she worked as an analyst at McKinsey & Company. From August 2004 to July 2012, she worked at Goldman Sachs (Asia) L.L.C. and successively held various positions, including the executive director. From July 2012 to September 2014, she served as managing director and head of China equity capital markets at Standard Chartered Bank. From September 2014 to August 2018, she served as executive director of strategic business development and investor relations at Global Brands Group Holding Limited, a company whose shares are listed on the Main Board of the Stock Exchange (stock code: 0787). She served as chief financial officer at ACEA Therapeutics, Inc, a company engaged in developing and delivering innovative treatments to life-threatening diseases from April 2019 to November 2019. Ms. Feng obtained her bachelor’s degree in computer appliance from Fudan University (fu'dan) in Shanghai, China in July 1998. She obtained a master’s degree in computer science from University of Virginia in the United States in August 2000, and a master of business administration degree from the University of Chicago Booth School of Business in the United States in March 2004.
Dr. Albert Tsai Jr.
Chief Medical Officer
Dr. Albert Tsai Jr.
Dr. Albert Tsai Jr., aged 48, was appointed as the CMO of our Group on June 1, 2021. He is primarily responsible for leading the Group to advance its assets through the clinical development process as well as supporting the post-approval medical affairs for the Group’s commercial products (e.g. safety, risk management, thought leader relationships). Dr. Tsai has 20 years of healthcare experience across the spectrum of pharmaceuticals, biotech, medical devices and healthcare consulting, as well as in various country markets including China, U.S., Japan and Southeast Asia. From 2019 to 2021, he served as the vice president, regional medical officer of the Asia-Pacific region at PPD Inc., a leading global contract research organization, responsible for business development and providing medical/scientific product development advisory to biotech companies in Asia. Prior to that, he served as vice president, Asia Pacific at The Medicines Company Hong Kong, a company listed on the NASDAQ (stock code: MDCO) from 2014 to 2019, where he developed and implemented the Asia expansion strategy for The Medicines Company Hong Kong with a primary focus on establishing their presence in China and Japan. From 1997 to 2014, he worked in various leading global pharmaceutical companies including Bayer Schering Pharma AG, Merck Sharp & Dohme (Asia) Ltd., Amgen Inc. and GE Healthcare Inc. in senior medical positions. Dr. Tsai obtained his doctor of medicine from Northwestern University and master of business administration in strategy and finance from University of Southern California.
Mr.Mauro Bove
Corporate Development Senior Vice President
Mr.Mauro Bove
Mr. Mauro Bove, aged 66, was appointed as the business development director of our Group on January 1, 2019. He is mainly responsible for overseeing business development activities and identifying new business opportunities and finalizing the relevant negotiations on a global basis. Mr. Bove has almost 40 years of business and management experience within the pharmaceutical industry working in Europe, North America and Asia. Mr. Bove led for many years until March 2014 the corporate and business development of Sigma-Tau Finanziaria S.p.A.. From May 2005 to December 2014, he served as a non-executive director of Lee’s Pharm. From December 2014 to December 2018, he served as the senior vice president of corporate and business development department of Lee’s Pharm, overseeing the business development activities and identifying new business opportunities for the group.
In addition to the above, Mr. Bove has also served as a director of many other private or listed pharmaceutical companies. He serves as a director at RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company listed on the OTCQB market under the ticker symbol “RGRX” in the United States; Kato Pharmaceuticals Incorporation, a privately held U.S. bio-pharmaceutical company dedicated to the development of novel therapies for pathologies of the eye with an emphasis on unmet medical needs; Adastra Pharmaceuticals Inc., a private U.S. clinical-stage biopharmaceutical company focused on providing novel solutions to advance patient care in oncology; and Eyesense AG, a European company focusing on the scientific R&D in the area of medical devices applied to the diabetes segment. Mr. Bove obtained his law degree from the University of Parma in Italy in July 1980. In 1985, he attended the Academy of American and International Law at International and Comparative Law Center in Texas, the United States.
Dr. Li Lok Yee Mandy
Research and Development Senior Vice President
Dr. Li Lok Yee Mandy
Dr. Li Lok Yee Mandy, aged 43, joined our Group in June 2016 and was appointed as the senior vice president, R&D of our Group on September 1, 2020. She is mainly responsible for facilitating the business development and execution of scientific strategies of research and project management (including both in-licensed and in-house developed pipeline products) of our Group. From 2004 to 2006, Dr. Li worked as a research associate at the department of chemical pathology of the Chinese University of Hong Kong. From 2006 to 2007, she worked as a post-doctoral fellow at the department of surgery of the University of Hong Kong. From October 2007 to April 2010, Dr. Li served as a research scientist of Bio-Cancer Treatment International Limited, a Hong Kong company focused on the R&D of innovative anticancer drugs, where she led a research team to conduct research on innovative anti-cancer, playing an active role in responding to FDA queries. Dr. Li joined Lee’s Pharm in February 2014, where she was first responsible for the R&D of new drugs, project management, business development and drug licensing, and further promoted to a senior vice president of Lee’s Pharm, leading and managing Lee’s Pharm’s R&D center. Dr. Li obtained her bachelor of science degree in biochemistry and her Ph.D. in biochemistry from the Chinese University of Hong Kong, in December 2000 and December 2004, respectively.
Mr. Zhang Guohui
Manufacturing & Logistics Senior Vice President
Mr. Zhang Guohui
Mr. Zhang Guohui, aged 47, joined our Group in June 2016 and was appointed as deputy general manager of our Group on July 1, 2016. He is mainly responsible for overseeing manufacturing and logistics function of our Group. Mr. Zhang has over 23 years of experience in pharmaceutical industry. Since his graduation in July 1997 and until June 2016, Mr. Zhang had been working in Lee’s Pharm for more than 18 years. He was first responsible for the R&D of new drugs, quality control and good manufacturing practice management and further promoted as the head of R&D of the company, where he accumulated extensive experience in the R&D and registration of new drugs, as well as project management. Mr. Zhang obtained his bachelor’s degree in biochemical engineering from the Beijing Institute of Light Industry (北京轻工业学院), currently known as Beijing Technology and Business University (北京工商大学) in Beijing, China in July 1997. He obtained his master’s degree in business administration from Asia International Open University (Macau) in January 2009.
Mr. Feng Jiang
Sales & Marketing Senior Vice President
Mr. Feng Jiang
Mr. Feng Jiang, aged 46, was appointed as sales and marketing director of our Group on October 1, 2020. He is primarily responsible for overseeing the branding, sales and marketing activities of our Group. From 2000 to 2006, Mr. Feng served at various China offices of multinational pharmaceutical companies as sales or medical representative. From January 2007 to April 2010, he worked for Eli Lilly Asia, Inc., where he was responsible for the promotion and sales of products in Guangdong Province and his last position was regional manager. From April 2010 to September 2020, he served successively as the regional manager and deputy director of the ophthalmic business department of Allergan Information Consulting (Shanghai) Co., Ltd, where he was responsible for the sales and marketing of the company’s ophthalmic pharmaceutical products and was granted several awards by the company in recognition of his great performance. Mr. Feng obtained his bachelor’s degree in biotechnology from South China Agricultural University (华南农业大学) in Guangdong Province, China in July 1999.
Ms. Yau Suk Yan
Financial Vice President. & Company Secretary
Ms. Yau Suk Yan
Ms.Yau was appointed as the VP, Financial Dept. & Company Secretary of our company on September 9, 2019. She is responsible for management and supervision of auditing, report analysis and budget control of our Group.
From September 2004 to January 2010, Ms. Yau served as a manager at KPMG. From February 2010 to July 2015, she was the financial controller and company secretary of Active Group Holdings Limited, currently known as Sino Energy International Limited (中能国际控股集团有限公司), a company whose shares are listed on the Main Board of the Stock Exchange (stock code: 1096), where she was in charge of finance management and audit of the group. From July 2015 to September 2019, Ms. Yau served as the financial controller and company secretary of Uni-Bio Science Group Limited (联康生物科技集团), a company whose shares are listed on the Main Board of Stock Exchange (stock code: 690), where she was responsible for finance management and audit of the group.
Ms. Yau obtained her bachelor’s degree of arts (with honors) in accountancy from the Hong Kong Polytechnic University in November 2004 and completed the CPA qualification programme and passed the professional examination for membership admission and was issued with a practicing certificate by Hong Kong Institute of Certified Public Accountants in August 2006. She has been a certified public accountant of the Hong Kong Institute of Certified Public Accountants since January 2008 and a fellow member of the Hong Kong Institute of Certified Public Accountants since March 2016.
External Consultant
Dr. Samir
Chandrakant Patel
Strategy Consultant
Dr. Samir Chandrakant Patel
Dr. Samir Chandrakant Patel, aged 61, was engaged by our Company as strategy consultant of our Group on April 9, 2020, to provide our Group with consulting services in relation to, among others, planning business strategies, sourcing business development opportunities, and providing protocol inputs and clinical development integration inputs. Dr. Patel has over thirty years of extensive experience in ophthalmology, including 10 years in academic medicine and 20 years in the ophthalmic pharmaceutical industry. He obtained his degree of doctor of medicine from the medical school of University of Massachusetts in the United States in 1985 and completed his residency in ophthalmology at the University of Chicago in 1990. Further, Dr. Patel completed his clinical retinal fellowship at the Massachusetts Eye and Ear Infirmary at the Harvard Medical School, being the primary teaching hospital of Harvard Ophthalmology. Dr. Patel was duly elected as a fellow by the American Academy of Ophthalmology in 1992. Dr. Patel commenced his practice in academic ophthalmology at the University of Chicago in 1992 where he eventually served as an associate professor of ophthalmology and the director of retina service, until July 2000. Dr. Patel further gained valuable insights and experience in the management and operation of pharmaceutical companies since 2000 when he first started his own business by co-founding Eyetech Pharmaceuticals, Inc., a biopharmaceutical company specializing in novel therapeutics to treat eye diseases, where he served as a director and chief of clinical and commercial strategy. In 2007, Dr. Patel co-founded Ophthotech Corporation, a biopharmaceutical company listed on the NASDAQ under the ticker symbol “OPHT” and specializing in the development of novel therapeutics to treat ophthalmic diseases (currently known as IVERIC bio, Inc. and listed on the NASDAQ Global Select Market under the ticker symbol “ISEE”), and served as the company’s founding CEO, president and vice chairman of its board of directors.
Dr. Parag
A. Majmudar
CONSULTANT
Dr. Parag A. Majmudar
Parag A. Majmudar, M.D., is the Consultant for Zhaoke Ophthalmology, and part of the senior management team to determine and oversee clinical research and development and help set overall corporate strategy.
Dr. Majmudar brings many years of clinical experience as a practicing ophthalmic surgeon in the United States in his role as President and Chief Medical Officer of Chicago Cornea Consultants, Ltd., as well as Associate Professor of Ophthalmology at Rush Medical College in Chicago, IL USA.
Dr. Majmudar was elected to the Phi Beta Kappa honor society and graduated with a Bachelor of Arts degree from Lehigh University in Bethlehem, Pennsylvania. After receiving his medical degree at the Medical College of Pennsylvania in Philadelphia, where he was a member of the prestigious Alpha Omega Alpha Honor Society, Dr. Majmudar completed his ophthalmology residency at the University of Chicago, serving as chief resident in the Department of Ophthalmology. He followed his residency with a subspecialty fellowship in cornea, external diseases and refractive surgery at Rush University Medical Center in Chicago. An active participant in clinical research activities, Dr. Majmudar is a highly regarded international lecturer and instructor on the subjects of corneal and refractive surgery.
Dr. Majmudar is an active member of the American Society of Cataract and Refractive Surgery as well as the American Academy of Ophthalmology, and he has received the Academy's Achievement Award and Senior Achievement Award. He is the former Chair of the AAO Refractive Surgery Program Committee, and is a former member of the ASCRS Refractive Surgery Clinical Committee. He serves on the International Council of the International Society of Refractive Surgery, and recently received an ISRS Achievement Award. He is the recipient of the 2020 Eversight “Gift of Sight” Award.
Dr. Majmudar also has a strong interest in venture capital growth opportunities within Ophthalmology and is a founding member of the Visionary Venture Fund, as well as a Scientific Advisor for InFocus Capital Partners. He also serves on the Medical Advisory Board of Med1Ventures.
Guangzhou Headquarters
Tel: 020-39062888
E-mail: info@zkoph.com
Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou
Hong Kong Headquarters
Tel: (852)23145100
E-mail: info@zkoph.com
Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong
Wechat
Guangzhou Headquarters
Tel: 020-39062888
E-mail: info@zkoph.com
Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou
Hong Kong Headquarters
Tel: (852)23145100
E-mail: info@zkoph.com
Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong
Wechat